Voya Investment Management LLC Increases Position in Viridian Therapeutics, Inc. (NASDAQ:VRDN)

Voya Investment Management LLC lifted its holdings in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN) by 5.1% in the fourth quarter, HoldingsChannel.com reports. The fund owned 21,397 shares of the company’s stock after acquiring an additional 1,038 shares during the period. Voya Investment Management LLC’s holdings in Viridian Therapeutics were worth $410,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also bought and sold shares of VRDN. Adage Capital Partners GP L.L.C. increased its position in shares of Viridian Therapeutics by 38.6% during the 4th quarter. Adage Capital Partners GP L.L.C. now owns 1,670,000 shares of the company’s stock valued at $32,014,000 after purchasing an additional 465,000 shares during the last quarter. Price T Rowe Associates Inc. MD increased its holdings in Viridian Therapeutics by 2,847.7% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 1,326,811 shares of the company’s stock worth $25,436,000 after buying an additional 1,281,799 shares during the last quarter. Dark Forest Capital Management LP bought a new stake in Viridian Therapeutics in the fourth quarter worth about $255,000. Silverarc Capital Management LLC purchased a new position in Viridian Therapeutics in the fourth quarter valued at about $1,917,000. Finally, Diadema Partners LP purchased a new stake in shares of Viridian Therapeutics during the 4th quarter worth approximately $948,000.

Wall Street Analyst Weigh In

Several equities analysts recently commented on the company. Needham & Company LLC dropped their price objective on Viridian Therapeutics from $38.00 to $36.00 and set a “buy” rating on the stock in a research note on Wednesday. Royal Bank of Canada dropped their price target on Viridian Therapeutics from $46.00 to $45.00 and set an “outperform” rating on the stock in a research report on Wednesday. The Goldman Sachs Group lowered their price objective on Viridian Therapeutics from $31.00 to $27.00 and set a “buy” rating on the stock in a research note on Wednesday. HC Wainwright reiterated a “buy” rating and issued a $34.00 target price on shares of Viridian Therapeutics in a research note on Wednesday, April 23rd. Finally, JMP Securities dropped their price target on shares of Viridian Therapeutics from $42.00 to $38.00 and set a “market outperform” rating on the stock in a research note on Wednesday. One investment analyst has rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $36.70.

Viridian Therapeutics Stock Down 1.9 %

VRDN opened at $12.54 on Friday. The firm has a market capitalization of $1.02 billion, a P/E ratio of -2.91 and a beta of 0.57. Viridian Therapeutics, Inc. has a one year low of $9.90 and a one year high of $27.20. The company has a fifty day moving average price of $13.71 and a 200-day moving average price of $17.49. The company has a debt-to-equity ratio of 0.04, a current ratio of 18.55 and a quick ratio of 18.55.

Viridian Therapeutics (NASDAQ:VRDN) last posted its earnings results on Tuesday, May 6th. The company reported ($0.87) EPS for the quarter, topping the consensus estimate of ($0.95) by $0.08. Viridian Therapeutics had a negative return on equity of 70.12% and a negative net margin of 85,127.16%. The business had revenue of $0.07 million during the quarter, compared to analysts’ expectations of $0.16 million. The firm’s revenue was up .0% on a year-over-year basis. Equities research analysts expect that Viridian Therapeutics, Inc. will post -4.03 earnings per share for the current fiscal year.

Viridian Therapeutics Company Profile

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.